| Indication | For treatment and management of epilepsy and anxiety disorder. |
| Pharmacodynamics | Clobazam is a barbiturate used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. |
| Mechanism of action | Clobazam binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is prolonged as a result. |
| Absorption | Bioavailability is 90%. |
| Volume of distribution | Not Available |
| Protein binding | 83% |
| Metabolism | Hepatic. Clobazam has two major metabolites: N-desmethyl-clobazam and 4'-hydroxyclobazam, the former of which is active. The demethylation is facilitated by CYP2C19, CYP3A4, and CYP2B6 and the 4'-hydroxyclobazam by CYP2C18 and CYP2C19. |
| Route of elimination | Not Available |
| Half life | 18 hours |
| Clearance | Not Available |
| Toxicity | Not Available |